You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameKW-3902
Accession NumberDB05360
TypeSmall Molecule
GroupsInvestigational
DescriptionKW-3902 is a compounds that is under clinical development by pharmaceutical company, NovaCardia. It is used for the treatment of congestive heart failure.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightAverage: 356.4619
Monoisotopic: 356.22122616
Chemical FormulaC20H28N4O2
InChI KeyPJBFVWGQFLYWCB-UHFFFAOYSA-N
InChI
InChI=1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22)
IUPAC Name
1,3-dipropyl-8-{tricyclo[3.3.1.0³,⁷]nonan-3-yl}-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
CCCN1C2=C(NC(=N2)C23CC4CC2CC(C3)C4)C(=O)N(CCC)C1=O
Pharmacology
IndicationInvestigated for use/treatment in congestive heart failure and kidney disease.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionKW-3902 (rolofylline),is an adenosine A1-receptor antagonist, on diuresis and renal function compared with placebo in patients with acute decompensated heart failure (ADHF). Plasma adenosine levels are elevated in patients with heart failure and adenosine A1 receptors in the kidney mediate vasoconstriction of afferent arterioles, reabsorption of sodium and water in proximal tubules, and tubuloglomerular feedback in the juxtaglomerular apparatus. Accordingly, inhibition of these receptors would be expected to increase renal blood flow and enhance diuresis. The effects of KW-3902 on renal function are consistent with those obtained with another adenosine A1-receptor antagonist in both experimental and human heart failure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Adenosine receptor A1ProteinunknownNot AvailableHumanP30542 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with KW-3902.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with KW-3902.Experimental, Illicit
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with KW-3902.Experimental, Illicit, Withdrawn
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with KW-3902.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with KW-3902.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with KW-3902.Illicit, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with KW-3902.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with KW-3902.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with KW-3902.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with KW-3902.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with KW-3902.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with KW-3902.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with KW-3902.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with KW-3902.Approved, Illicit
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with KW-3902.Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with KW-3902.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with KW-3902.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with KW-3902.Approved, Illicit, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with KW-3902.Approved, Illicit
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with KW-3902.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with KW-3902.Approved, Illicit
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with KW-3902.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with KW-3902.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with KW-3902.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with KW-3902.Illicit
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with KW-3902.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with KW-3902.Approved, Illicit
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with KW-3902.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with KW-3902.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with KW-3902.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with KW-3902.Approved, Illicit
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with KW-3902.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with KW-3902.Approved, Investigational, Vet Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with KW-3902.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with KW-3902.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with KW-3902.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with KW-3902.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with KW-3902.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with KW-3902.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with KW-3902.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S: The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007 Oct;13(8):609-17. [PubMed:17923351 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9531
Caco-2 permeable-0.6414
P-glycoprotein substrateSubstrate0.7637
P-glycoprotein inhibitor IInhibitor0.7726
P-glycoprotein inhibitor IINon-inhibitor0.7673
Renal organic cation transporterNon-inhibitor0.6473
CYP450 2C9 substrateNon-substrate0.7638
CYP450 2D6 substrateNon-substrate0.8117
CYP450 3A4 substrateSubstrate0.6349
CYP450 1A2 substrateInhibitor0.7733
CYP450 2C9 inhibitorNon-inhibitor0.6371
CYP450 2D6 inhibitorNon-inhibitor0.8456
CYP450 2C19 inhibitorNon-inhibitor0.6767
CYP450 3A4 inhibitorInhibitor0.5975
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6423
Ames testNon AMES toxic0.5956
CarcinogenicityNon-carcinogens0.8656
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity3.2033 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8659
hERG inhibition (predictor II)Inhibitor0.6043
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.125 mg/mLALOGPS
logP4.11ALOGPS
logP3.27ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)7.83ChemAxon
pKa (Strongest Basic)-0.72ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area69.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity99.06 m3·mol-1ChemAxon
Polarizability40.67 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alkaloids and derivatives. These are naturally occurring chemical compounds that contain mostly basic nitrogen atoms. This group also includes some related compounds with neutral and even weakly acidic properties. Also some synthetic compounds of similar structure are attributed to alkaloids. In addition to carbon, hydrogen and nitrogen, alkaloids may also contain oxygen, sulfur and more rarely other elements such as chlorine, bromine, and phosphorus.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassNot Available
Sub ClassNot Available
Direct ParentAlkaloids and derivatives
Alternative Parents
Substituents
  • Alkaloid or derivatives
  • Xanthine
  • Purinone
  • 6-oxopurine
  • Purine
  • Imidazopyrimidine
  • Pyrimidone
  • Pyrimidine
  • Heteroaromatic compound
  • Vinylogous amide
  • Imidazole
  • Azole
  • Urea
  • Lactam
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Purine nucleoside binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
ADORA1
Uniprot ID:
P30542
Molecular Weight:
36511.325 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:24 / Updated on August 17, 2016 12:24